Cancer Treatment Centers of America Selects WIRB-Copernicus Group to Facilitate the Expansion of its Clinical Research Program
Strategy will enable CTCA to expand its clinical research capabilities while maintaining the highest standard of human subject protection
WIRB-Copernicus Group (WCG), the world’s largest provider of regulatory and ethical review services and software to support clinical research, announced today that it has been chosen by Cancer Treatment Centers of America® (CTCA) to help expand its clinical research program. WCG will assist CTCA in the centralization and optimization of its regulatory and ethical review process, allowing CTCA to manage a higher volume of cutting-edge research while maintaining the highest degree of participant protection. CTCA is a leader in integrative cancer care with a national network of five state-of-the-art hospitals in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa.
WCG Chairman and CEO Donald A. Deieso, Ph.D., commented, “CTCA is recognized as a leader in the field of oncology, offering comprehensive and innovative therapies to treat cancer patients. It is therefore no surprise that CTCA is assuming a more prominent role in the conduct of oncological research and follows the most rigorous, industry-leading practices to assure participant safety and regulatory compliance. We are proud to partner with CTCA and help grow its clinical research program.”
“At CTCA, we are committed to offering our patients leading-edge cancer treatments through the continued expansion of our portfolio of evidence-based treatment options. To support our growth, we are adopting new practices to make the ethical and regulatory oversight of our clinical trials more efficient,” said President, CTCA Medicine and Science, Maurie Markman, MD. “WCG, with its significant experience in reviewing oncology research, is an ideal partner to help us expand our research program while maintaining the highest standard of human subject protection.”
WCG Oncology™, WCG’s oncology-focused oversight division, will partner with CTCA in this process. Composed of industry luminaries, expert consultants and three dedicated institutional review boards (IRBs), WCG Oncology provides a thorough review of oncology research, and brings a deep understanding of the changing oncology research landscape, cutting-edge theory, scientific methods, technologies, and study designs to the process.
CTCA will also benefit from WCG’s guidance in the centralization and optimization of its internal IRB. Composed of CTCA experts, and administered according to WCG’s standard operating procedures, this CTCA panel is fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP) through Western IRB (WIRB). Achieved by only 200 of approximately 3,000 IRBs in the United States, AAHRPP-accreditation confirms CTCA’s adherence to the highest standards of ethical review and human subject protection.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
